Fast Five Quiz: Managing Progression of Relapsing-Remitting Multiple Sclerosis

Christopher Luzzio, MD; Kerstin Hellwig, MD


July 01, 2022

For patients with clinically isolated syndrome, immediate initiation of DMT is recommended to minimize CNS damage. Early treatment is associated with improved long-term outcomes and slower disability progression compared with delayed treatment. Because subclinical neurologic injury is believed to continue in patients with MS even in the absence of acute relapses and stable MRI scans, intervention as soon as possible is essential to minimize CNS damage. Before a DMT is considered, an accurate diagnosis of MS must be established. Cerebrospinal fluid can aid in the differential diagnosis.

Glatiramer acetate (Copaxone) is a synthetic polypeptide approved for reducing the frequency of relapses in patients with RRMS, including patients who have experienced a first clinical episode and have MRI features consistent with MS. Although its mechanism of action is not well understood, it is thought that this agent affects immune processes involved in the pathogenesis of MS.

The American Academy of Neurology (AAN) and the European Committee of Treatment and Research in Multiple Sclerosis/European Academy of Neurology (ECTRIMS/EAN) offer guidance on the initiation, switching, and stopping of DMTs.

Learn more about DMTs.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.